Template:Dgfn2015 Mo 7:00 PCSK9

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
''dataset not ready 30 citations remianig'''
+
[http://nephrologie.conference2web.com/contentsessions/1945 DGFN2015 Neue Wirkansätze in der Hyperlipidämie - Stellenwert für die Nephrologie (Rump-LC,Gouni-Berthold-I)] see session video
  
 +
==Lipidmanagement bei CKD-Patienten, Was ist belegt, was zu beachten. (Wanner-W)==
 
{{utp|p=12612979|t=A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease |pdf=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386%2802%2969247-9?showall=true|usr=|}}
 
{{utp|p=12612979|t=A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease |pdf=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386%2802%2969247-9?showall=true|usr=|}}
  
Line 8: Line 9:
  
 
{{utp|p=16214597|t=Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis  of data from 90,056 participants in 14 randomised trials of statins |pdf=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736%2805%2967394-1?showall=true|usr=|}}
 
{{utp|p=16214597|t=Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis  of data from 90,056 participants in 14 randomised trials of statins |pdf=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736%2805%2967394-1?showall=true|usr=|}}
 +
 +
==PCSK9-Inhibitoren: ein neuer Wirkmechanismus (Schettler-V)==
  
 
{{utp|p=25815993|t=A century of cholesterol and coronaries: from plaques to genes to statins |pdf=http://www.cell.com/cell/abstract/S0092-8674%2815%2900079-3?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867415000793%3Fshowall%3Dtrue|usr=|}}
 
{{utp|p=25815993|t=A century of cholesterol and coronaries: from plaques to genes to statins |pdf=http://www.cell.com/cell/abstract/S0092-8674%2815%2900079-3?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867415000793%3Fshowall%3Dtrue|usr=|}}
Line 57: Line 60:
  
 
{{tp|p=25915661|t=Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis |pdf=http://annals.org/data/Journals/AIM/934197/0000605-201507070-00009.pdf|usr=|}}
 
{{tp|p=25915661|t=Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis |pdf=http://annals.org/data/Journals/AIM/934197/0000605-201507070-00009.pdf|usr=|}}
 +
 +
==Was kommt nach den Statinen ? Aktuelles zu PCSK9 Antikörpern (König-W)==
 +
 +
{{tp|p=25082583|t=Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials |pdf=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(14)02704-1|usr=|}}
 +
 +
{{utp|p=20102893|t=Meta-analysis of comparative efficacy of incre